AMA says CVS-Aetna deal conditions aren’t good enough

In the wake of the Department of Justice clearing the path for CVS Health to merge with Aetna in a $69 billion deal, the American Medical Association still doesn’t think the conditions mandated by the Justice Department go far enough to quell anticompetition fears.

Aetna is required to sell off its Medicare Part D prescription drug plan for the merger with CVS Health to go through, the DOJ mandated Wednesday.

Multiple associations, legislators and regulators have voiced their concerns over the deal, which is one of the biggest in the healthcare space and brings together the nation’s largest pharmacy retailer and the third largest health insurance provider.

Aetna announced it agreed to sell its Medicare Part D business to Wellcare Health Plans last month. The Justice Department gave its preliminary approval for the deal to move forward on Wednesday with the caveat that Aetna complete its divestiture.

“While the AMA welcomes the U.S. Department of Justice (DOJ) requiring Aetna to divest its Medicare Part D drug plan business, we are disappointed that the DOJ did not go further by blocking the CVS-Aetna merger,” AMA said in a statement.

AMA voiced its opposition to the CVS-Aetna deal in August, urging regulators to block the merger over anti-competition concerns.

“We now urge the DOJ and state antitrust enforcers to monitor the post-merger effects of the Aetna acquisition by CVS Health on highly concentrated markets in pharmaceutical benefit management services, health insurance, retail pharmacy and specialty pharmacy,” AMA said Wednesday.

AMA is the nation’s largest association of physicians and medical students and was founded in 1847.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup